Loading Results
We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.

Liver Diseases Center

INSTITUTE
University Hospitals Digestive Health Institute

MEDICAL DIRECTOR
Pierre M. Gholam, MD
Pierre.Gholam@UHhospitals.org

SURGICAL DIRECTOR

KEY CONTACTS
Anthony Post, MD; S. Martin Cohen, MD

APPOINTMENT LINE
For hospital transfers, please call 216-844-1111.

Coordinators and Contact Information
• For transplant referrals and intake, please call Pamela Diamond at 216-844-3689.
• For medical referrals to the Liver Diseases Center, please call Rhonda Wynn at 216-844-5387.
• For referrals for surgical treatment at the Liver Diseases Center, please call Linda Little at 216-844-0489, option 2.
• For hospital transfers, please call 216-844-1111.

Conditions Treated

  • Chronic hepatitis C infection
  • Non-alcoholic steatohepatitis (NASH)
  • Fatty liver disease
  • End-stage liver disease requiring liver transplantation
  • Cirrhosis of the liver
  • Hepatocellular carcinoma (primary liver cancer)
  • Cholangiocarcinoma (bile duct cancer)
  • Benign liver tumors (hemangioma, adenoma, FNH)

Therapies

  • Liver transplantation
  • Antiviral therapy for HCV infection
  • Surgical resection of malignant and benign liver tumors
  • Radiofrequency ablation for hepatocellular carcinoma
  • Transarterial chemoembolization (TACE) for hepatocellular carcinoma
  • Transarterial radioembolization (TARE/Y90) for hepatocellular carcinoma
  • Systemic chemotherapy for hepatocellular carcinoma

Liver Diseases Center

  • Chronic hepatitis B infection
  • Alcoholic liver disease
  • Primary biliary cholangitis
  • Primary sclerosing cholangitis
  • Hereditary hemochromatosis
  • Vascular liver disease (portal vein thrombosis, Budd-Chiari syndrome)
  • Alpha one antitrypsin deficiency
  • Wilson disease
  • Stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma
  • Antiviral therapy for hepatitis B
  • Clinical trials for reversal of liver fibrosis/cirrhosis, fatty liver disease, hepatitis C and liver cancer
  • Treatment of cholestatic liver disease
  • Genetic testing and counseling for inherited disorders of the liver
  • Phlebotomy and follow-up of hereditary hemochromatosis

Distinguishing Features

  • Expedited evaluation of candidacy for liver transplantation for the patients who are most ill
  • Multidisciplinary hepatobiliary tumor board, with broad participation from expert surgeons, hepatologists, medical oncologists, interventional radiologists, pathologists, radiation oncologists and palliative care specialists
  • Nationally and internationally published quality and outcomes data
  • Access to state-of-the-art treatment, including early-phase clinical trials for patients with liver cancer
  • One of the largest hepatitis C treatment clinics in the U.S., with more than 1,000 patients treated and cured in the last two years
  • Access to state-of-the-art clinical trials for all the latest investigational treatments for fatty liver disease
  • Access to first-ever clinical trials for reversal of cirrhosis and liver fibrosis
  • NIH-funded clinical and research program in alcoholic liver disease